Natera Signatera

Natera has launched Signatera, a research-use-only circulating tumor DNA assay. Signatera consists of analyzing whole-exome sequencing data from a patient's tumor sample to design a targeted, custom-designed assay to analyze 16 or more mutations that were identified in the tumor sample. According to Natera, the assay can detect variant allele frequencies down to 0.01 percent and is optimized to achieve high specificity by requiring detection of multiple mutations for a ctDNA-positive call, leading to fewer false positives.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.